Experimental HCV Drugs
Experimental HCV Drugs
High Rate of Sustained Response with Interferon-Free Daclatasvir + Asunaprevir for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 24 January 2012 00:00
- Written by Liz Highleyman
A dual oral regimen of Bristol-Myers Squibb's hepatitis C virus (HCV) protease inhibitor asunaprevir (formerly BMS-650032) and HCV NS4A inhibitor daclatasvir (BMS-790052) cleared the virus in one-third of genotype 1 prior null responders to prior interferon-based therapy, and both of those with genotype 1b, according to data published in the January 19, 2012, New England Journal of Medicine.
Achillion, Presidio, Idenix Announce HCV Drug Pipeline Developments
- Details
- Category: HCV Treatment
- Published on Tuesday, 17 January 2012 00:00
- Written by Press Release
Three companies developing direct-acting antiviral agents (
DAAs) for hepatitis C virus (HCV) infection recently announced progress on new experimental drug candidates.
AASLD 2011: Recombinant Hepatitis C Vaccine TG404 Shows Promise in Phase 2 Trial
- Details
- Category: HCV Treatment
- Published on Tuesday, 20 December 2011 00:00
- Written by Transgene
Transgene's recombinant poxvirus therapeutic hepatitis C virus (HCV) vaccine, TG4040, demonstrated good tolerability and increased the likelihood of viral suppression at 12 weeks when administered with pegylated interferon plus ribavirin, according to data from an international Phase 2 clinical trial reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in San Francisco. 
Pharmasset Halts Testing of HCV Polymerase Inhibitor PSI-938 Due to Liver Problems
- Details
- Category: HCV Treatment
- Published on Tuesday, 03 January 2012 00:00
- Written by Press Release
Pharmasset announced in December that it would change the design of its ongoing QUANTUM trial to discontinue treatment with its hepatitis C virus (HCV) nucleotide polymerase inhibitor PSI-938, after routine safety monitoring revealed liver function abnormalities.
Novel P7 Inhibitor BIT225 Improves Hepatitis C Response, also Inhibits HIV
- Details
- Category: HCV Treatment
- Published on Friday, 16 December 2011 00:00
- Written by Press Release
At the HepDART drug development conference this month researchers presented interim data from a Phase 2 clinical trial showing that a novel direct-acting antiviral known as BIT225 improved the likelihood of virological response at 12 weeks when added to pegylated interferon/ribavirin.
More Articles...
- Merck and Roche to Collaborate on Combination Regimens for Hepatitis C
- Two New Nucleotide HCV Polymerase Inhibitors Enter Clinical Trials
- New Hepatitis C NS5A Inhibitor ACH-2928 Shows Potent Antiviral Activity
- AASLD 2011: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV
Web Design and Development by